A first-in-human trial (GDFATHER-1/2a, NCT04725474) evaluated the anti-GDF-15 antibody visugromab in combination with nivolumab in patients with advanced cancers resistant to anti-PD-1/PD-L1 therapies. The gene discussed is CD274; the disease is cancer.